DSDebasis Sen

Debasis Sen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Debasis Sen has a total of 11 co-authors. Here are the top co-authors by number of shared publications:

  • Sanjay Jain

    Department of Pharmaceutical Sciences, Dr. Harisingh Gour Vishwavidyalaya (A Central University), Sagar 470003, M.P., India

    8 shared publications
  • Sunny Rathee

    Department of Pharmaceutical Sciences, Dr. Harisingh Gour Vishwavidyalaya (A Central University), Sagar, Madhya Pradesh,470003, India

    7 shared publications
  • Vishal Pandey

    Department of Pharmaceutical Sciences, Dr. Harisingh Gour Vishwavidyalaya (A Central University), Sagar, Madhya Pradesh, 470003, India

    7 shared publications
  • Sakshi Soni

    Department of Pharmaceutical Sciences, Dr. Harisingh Gour Vishwavidyalaya (A Central University), Sagar, Madhya Pradesh,470003, India

    4 shared publications
  • Umesh Kumar Patil

    Department of Pharmaceutical Sciences, Dr. Harisingh Gour Vishwavidyalaya (A Central University), Sagar, Madhya Pradesh,470003, India

    4 shared publications
  • Amit Sahu

    Department of Pharmaceutical Sciences, Dr. Harisingh Gour Vishwavidyalaya, (A Central University), Sagar, MadhyaPradesh, 470003, India

    1 shared publication

Latest Publications

  • Open Access

    Smart microneedles for precision oncology: Bridging immunotherapy, biosensing, and AI-driven drug delivery

    by Vishal Pandey, Debasis Sen, Utkarsh Sharma, Sunny Rathee, Sakshi Soni

  • Innovative Nanoparticle-based Therapeutic Strategies: Overcoming Biological Barriers for Enhanced Efficacy

    by Sunny Rathee, Sakshi Soni, Debasis Sen, Sanjay K. Jain

    The Blood-Brain Barrier (BBB) poses a formidable challenge for drug delivery to the Central Nervous System (CNS) due to its selective permeability and robust defense mechanisms. This review provides a comprehensive examination of the anatomical structure, physiology, and physiological challenges of the BBB, along with innovative approaches for overcoming these barriers to enhance CNS drug delivery. The BBB is primarily composed of endothelial cells, pericytes, and astrocytic end-feet, reinforced by tight junctions that tightly regulate the passage of substances into the brain parenchyma. Various transport mechanisms, including carrier-mediated transport, receptor-mediated transport (e.g., via LDL and transferrin receptors), absorptive-mediated transport, and active efflux transport, govern the selective influx and efflux of molecules across the BBB to maintain CNS homeostasis. Biological approaches harness endogenous transport mechanisms to facilitate drug delivery across the BBB, while chemical approaches leverage nanotechnology to engineer nanoparticles capable of traversing the barrier. These include liposomes, solid-lipid nanoparticles, polymeric nanoparticles, and inorganic nanoparticles, each designed with specific parameters such as particle size, shape, and surface charge to optimize drug delivery. Drug loading strategies, such as covalent bonding and non-covalent adsorption, enhance the encapsulation and release of therapeutic agents from nanoparticles. Furthermore, the incorporation of ligands facilitates receptor targeting and protein corona formation, enhancing nanoparticle properties and improving BBB penetration. By synthesizing recent advancements in BBB permeation strategies, this review aims to provide insights into the development of effective therapies for neurological disorders, ultimately advancing the field of CNS drug delivery.

  • Top Cited Papers

    Exploring Saffron's Therapeutic Potential: Insights on Phytochemistry, Bioactivity, and Clinical Implications

    by Debasis Sen, Sunny Rathee, Vishal Pandey, Sanjay K. Jain

    Saffron, derived from the Crocus sativus plant, has been revered for centuries for its culinary, medicinal, and cultural significance. This review provides a comprehensive overview of saffron's chemical constituents and phytochemistry, elucidating its rich profile of bioactive compounds. Emphasis is placed on exploring the bio-accessibility, bioavailability, and bioactivity of saffron's phytochemicals, laying the foundation for understanding its pharmaceutical significance. The pharmaceutical importance of saffron and its phytochemicals is thoroughly examined, focusing on their diverse therapeutic properties. These include anticancer, antidiabetic, antioxidant, antimicrobial, anti-inflammatory, antinociceptive, anticonvulsant, antidepressant, learning and memory enhancement, cardiovascular, and antihypertensive properties. Such multifaceted pharmacological activities underscore saffron's potential as a valuable medicinal resource. Clinical studies investigating the efficacy and safety of saffron in various health conditions are synthesized, providing insights into its clinical applications. Moreover, toxicity assessments in animal models, encompassing acute, subacute, subchronic, and developmental toxicity, are discussed to delineate the safety profile of saffron and its bioactive constituents. Finally, recent advances and future perspectives in saffron research are highlighted, underscoring emerging trends and potential avenues for further exploration. This review serves as a comprehensive resource for researchers, clinicians, and stakeholders interested in harnessing the therapeutic potential of saffron while ensuring its safe and effective utilization in healthcare settings.


  • Unlocking Toll-Like Receptors: Targeting Therapeutics for Respiratory Tract Infections and Inflammatory Disorders

    by Vishal Pandey, Debasis Sen, Sunny Rathee, Sakshi Soni, Shashank Mishra, Sanjay K. Jain, Umesh K. Patil

    The Toll-like Receptors (TLRs) family has significantly enhanced the understanding of innate immune responses by identifying and responding to various microbes or host-derived organisms. TLRs contribute to these responses by increasing the levels of cytokines, interleukins, and other inflammatory mediators through multiple pathways. Located both intracellularly and on the surface of various cells and tissues, including vascular smooth muscles (VSMs) and myocardium cells, TLRs play distinct roles in innate immune activation, such as recognizing pathogen-associated molecular patterns (PAMPs) and activating downstream signaling pathways. In the context of COVID-19, TLRs are critically involved in the pathophysiology by mediating excessive inflammatory responses that exacerbate disease severity, influencing both the acute phase and long-term outcomes. It has been observed that inflammatory diseases such as atherosclerosis, viral myocarditis, and other comorbidities associated with the spread of COVID-19 have increased, although the exact mechanisms remain not fully understood. Nonetheless, there is evidence of TLR-mediated increased pro-inflammatory signaling by different mechanisms in these diseases. This review explains the role of TLRs in various inflammatory diseases related to COVID-19, including viral myocarditis, acute lung infections, and atherosclerosis. Furthermore, the review discusses various herbal drugs, such as Platycodon grandiflorum, Acanthopanax senticosus, Scutellaria baicalensis Georgi, and Engelhardia roxburghiana, and their mechanisms of action on TLRs, including NF-κB, MyD88-dependent, MyD88-independent pathways, and Plasmacytoid DCs. Enhanced clarity on TLRs' specific contributions to COVID-19 pathophysiology and stronger evidence supporting herbal interventions targeting TLRs could improve the impact and applicability of these findings in clinical settings.


  • Integrating Nanotechnology and Phytochemicals: Innovative Approaches for the Management of Melasma

    by Devyani Rajput, Sunny Rathee, Amit Sahu, Debasis Sen, Sanjay K. Jain, Umesh K. Patil

    Melasma, a chronic skin disorder characterized by hyperpigmentation, poses significant challenges in dermatological and cosmetic care. Nanotechnology offers transformative solutions by enhancing the delivery and efficacy of hypopigmenting agents through advanced drug delivery systems, including liposomes, nanoemulsions, solid lipid nanoparticles, and polymeric nanoparticles. These nanocarriers improve the stability, solubility, and skin penetration of active compounds, effectively targeting melanin synthesis pathways. Tailored approaches enable treatments to address specific melasma types, with lipid-based carriers optimized for epidermal melasma and deeperpenetrating systems like transfersomes and ethosomes suitable for dermal and mixed variants. Additionally, gold nanoparticles (AuNPs) introduce novel therapeutic potential with their tyrosinaseinhibiting and antioxidant properties. While formulation advancements have shown promise in optimizing nanocarrier distribution and drug delivery efficiency, challenges such as scalability, cost, and regulatory barriers remain. Initial studies highlight the potential of nanocarrier-based therapies, but robust in vivo trials are essential to validate safety and clinical efficacy. The integration of nanotechnology into melasma treatment represents a paradigm shift, offering innovative, patient-centered solutions that address the limitations of conventional therapies and pave the way for more effective and targeted management strategies.

  • Comprehending Alzheimer's Disease: Molecular Mechanisms and Treatment Strategies

    by Sunny Rathee, Vishal Pandey, Sakshi Soni, Debasis Sen, Sanjay K. Jain

    Alzheimer's disease (AD) is a complex neurodegenerative disorder and a growing global health challenge, driven by increasing life expectancy and an aging population. This review provides a comprehensive exploration of AD pathophysiology, integrating current hypotheses such as the amyloid cascade, tau protein pathology, cholinergic dysfunction, neuroinflammation, vascular contributions, and potential infection-related mechanisms. The multifactorial etiology of AD, encompassing genetic predispositions and environmental factors, underscores its intricate nature. This study delves into the diagnostic advancements, including the identification and utilization of biomarkers for early detection and disease monitoring. Therapeutic approaches are critically evaluated, highlighting anti-amyloid and anti-tau strategies, alongside emerging innovations in stem cell therapy and nanobiotechnology. A detailed examination of clinical trials offers insights into the achievements and setbacks of translating research into effective treatments. By synthesizing epidemiological trends, molecular mechanisms, and therapeutic developments, this review aims to advance our understanding of AD and foster collaborative efforts to develop transformative solutions. It emphasizes the urgency of addressing this multifaceted disease, presenting a nuanced perspective on its complexity while illuminating future directions for research and clinical practice.


  • Comprehensive Insights into Pathophysiology of Alzheimer's Disease: Herbal Approaches for Mitigating Neurodegeneration

    by Debasis Sen, Sunny Rathee, Vishal Pandey, Sanjay K. Jain, Umesh K. Patil

    Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline, memory loss, and functional impairment. Despite extensive research, the exact etiology remains elusive. This review explores the multifaceted pathophysiology of AD, focusing on key hypotheses such as the cholinergic hypothesis, hyperphosphorylated Tau Protein and Amyloid β hypothesis, oxidative stress hypothesis, and the metal ion hypothesis. Understanding these mechanisms is crucial for developing effective therapeutic strategies. Current treatment options for AD have limitations, prompting the exploration of alternative approaches, including herbal interventions. Cholinesterase inhibitors, targeting the cholinergic hypothesis, have shown modest efficacy in managing symptoms. Blocking Amyloid β (Aβ) and targeting hyperphosphorylated tau protein are under investigation, with limited success in clinical trials. Oxidative stress, implicated in AD pathology, has led to the investigation of antioxidants. Natural products, such as Punica granatum Linn, Radix Scutellariae, and Curcuma longa have demonstrated antioxidant properties, along with anti-inflammatory effects, offering potential neuroprotective benefits. Several herbal extracts, including Ginkgo biloba, Bacopa monnieri, and Withania somnifera, have shown promise in preclinical studies. Compounds like Huperzine A, Melatonin, and Bryostatin exhibit neuroprotective effects through various mechanisms, including cholinergic modulation and anti-inflammatory properties. However, the use of herbal drugs for AD management faces limitations, including standardization issues, variable bioavailability, and potential interactions with conventional medications. Additionally, the efficacy and safety of many herbal products remain to be established through rigorous clinical trials. This review also highlights promising natural products currently in clinical trials, such as Resveratrol and Homotaurine, and their potential impact on AD progression. DHA, an omega-3 fatty acid, has shown cognitive benefits, while Nicotine is being explored for its neuroprotective effects. In conclusion, a comprehensive understanding of the complex pathophysiology of AD and the exploration of herbal interventions offer a holistic approach for managing this devastating disease. Future research should address the limitations associated with herbal drugs and further evaluate the efficacy of promising natural products in clinical settings.


  • Phytovesicular Nanoconstructs for Advanced Delivery of Medicinal Metabolites: An In-Depth Review

    by Vishal Pandey, Sunny Rathee, Debasis Sen, Sanjay K. Jain, Umesh K. Patil

    : Phytochemicals, the bioactive compounds in plants, possess therapeutic benefits, such as antimicrobial, antioxidant, and pharmacological activities. However, their clinical use is often hindered by poor bioavailability and stability. Phytosome technology enhances the absorption and efficacy of these compounds by integrating vesicular systems like liposomes, niosomes, transfersomes, and ethosomes. Phytosomes offer diverse biological benefits, including cardiovascular protection through improved endothelial function and oxidative stress reduction. They enhance cognitive function and protect against neurodegenerative diseases in the nervous system, aid digestion and reduce inflammation in the gastrointestinal system, and provide hepatoprotective effects by enhancing liver detoxification and protection against toxins. In the genitourinary system, phytosomes improve renal function and exhibit anti-inflammatory properties. They also modulate the immune system by enhancing immune responses and reducing inflammation and oxidative stress. Additionally, phytosomes promote skin health by protecting against UV radiation and improving hydration and elasticity. Recent patented phytosome technologies have led to innovative formulations that improve the stability, bioavailability, and therapeutic efficacy of phytochemicals, although commercialization challenges like manufacturing scalability and regulatory hurdles remain. Secondary metabolites from natural products are classified into primary and secondary metabolites, with a significant focus on terpenoids, phenolic compounds, and nitrogen-containing compounds. These metabolites have notable biological activities: antimicrobial, antioxidant, antibiotic, antiviral, anti-inflammatory, and anticancer effects. In summary, this review amalgamates the latest advancements in phytosome technology and secondary metabolite research, presenting a holistic view of their potential to advance therapeutic interventions and contribute to the ever-evolving landscape of natural product-based medicine.


  • Advances in Understanding and Managing Alzheimer's Disease: From Pathophysiology to Innovative Therapeutic Strategies

    by Sunny Rathee, Debasis Sen, Vishal Pandey, Sanjay K. Jain

    : Alzheimer's disease (AD) is a debilitating neurodegenerative disorder characterized by the presence of amyloid-β (Aβ) plaques and tau-containing neurofibrillary tangles, leading to cognitive and physical decline. Representing the majority of dementia cases, AD poses a significant burden on healthcare systems globally, with onset typically occurring after the age of 65. While most cases are sporadic, about 10% exhibit autosomal forms associated with specific gene mutations. Neurofibrillary tangles and Aβ plaques formed by misfolded tau proteins and Aβ peptides contribute to neuronal damage and cognitive impairment. Currently, approved drugs, such as acetylcholinesterase inhibitors and N-methyl D-aspartate receptor agonists, offer only partial symptomatic relief without altering disease progression. A promising development is using lecanemab, a humanized IgG1 monoclonal antibody, as an immune therapeutic approach. Lecanemab demonstrates selectivity for polymorphic Aβ variants and binds to large soluble Aβ aggregates, providing a potential avenue for targeted treatment. This shift in understanding the role of the adaptive immune response in AD pathogenesis opens new possibilities for therapeutic interventions aiming to address the disease's intricate mechanisms. This review aims to summarize recent advancements in understanding Alzheimer's disease pathophysiology and innovative therapeutic approaches, providing valuable insights for both researchers and clinicians.